The objective of this proposal is to complete the engineering development and pre-clinical testing of the SCR SVAD system to provide partial cardiac assist in patients with less advanced stage heart failure (HF). HF is increasing worldwide and represents a major burden in terms of health care resources and costs. Despite advances in medical care, prognosis with HF remains poor, especially in advanced stages. Currently, it requires a major operative intervention and cardiopulmonary bypass (CPB), which have been associated with significant adverse event rates and long recovery. The high cost of the intervention and patient follow-up has limited widespread acceptance. The SVAD system consists of a miniaturized axial flow pump (platinum alloy impeller and vane diffuser), inflow cannulation to the left atrium, and outflow graft anastomosis to axillary artery. The SVAD pump (6 cm length, 2 cm diameter, 40 g weight) is implanted through a right lateral mini-thoracotomy. The clinical benefits of the SVAD include: eliminates major surgery (sternotomy), LV apical coring, and aortic anastomosis;performed 'off pump'(no CPB);pump placement in subclavicular pocket facilitates implant (and explant) procedure(s);and superior hydrodynamic performance (5 lpm @ 100 mmHg) with low power requirements. In this phase I-II proposal, we will demonstrate feasibility and complete engineering development and pre- clinical testing of the SVAD to support a FDA submission for phase one (n=10) and phase two (n=300) clinical trials. To achieve this objective, we will complete the engineering development and design freeze of the SVAD system with Good Manufacturing Practices (GMP) specifications for a human implant quality system;demonstrate efficacy and biocompatibility by completing Validation and Verification (V&V) testing (fatigue), anatomical fit and surgical procedure study (human cadaver, n=4), and in vivo acute (n=4), chronic 7-day (n=6), and chronic 45-day (n=8) Good Laboratory Practices (GLP) study. The pre-clinical, V&V, GMP, and GLP study data will be used to support an IDE application for a clinical trial in HF patients. Our long-term goal is to clinically translate the SCR SVAD to treat earlier stage HF patients, using miniaturized partial support device, and less invasive surgical tools and procedures to improve patient outcomes and restore quality of life.

Public Health Relevance

SCR (Louisville KY) is developing the SVAD system in partnership with HeartWare (Miami Lakes FL). The SVAD is a miniaturized left ventricular assist device (6 cm length, 2 cm diameter, 40 g weight) with atrial inflow and aortic outflow cannulation (SVAD) implanted via a mini-thoracotomy with pump placement in a right subclavicular pocket and provide partial support (1-5 lpm) to treat patients with less advanced heart failure. The clinical benefits of this technology are less invasive surgical procedure that will shorten recover time and lower hospital costs while improving patient outcomes and restoring quality of life.

Agency
National Institute of Health (NIH)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
1R44HL123120-01
Application #
8713455
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Baldwin, Tim
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Scr, Inc.
Department
Type
DUNS #
City
Louisville
State
KY
Country
United States
Zip Code
40202